March 24, 2014
Investigation Report on China Atorvastatin Market, 2009-2018
DUBLIN, March 24, 2014 /PRNewswire/ --
Research and Markets (
http://www.researchandmarkets.com/research/zkjlpz/investigation) has announced the
addition of the "Investigation Report on China Atorvastatin Market, 2009-2018"
[http://www.researchandmarkets.com/research/zkjlpz/investigation ] report to their
The prevalence rate of abnormal blood lipid in China is lower than that in most
developed countries, but the average serum TC level of Chinese people is upgrading for the
economic development and lifestyle change. Meanwhile, diabetes and metabolic syndromes are
very common in China.
According to statistics, the prevalence rate of abnormal blood lipid is above 20% in
the group aged at 18 or above. The total number of patients exceeds 200 million.
Blood lipid-lowering drugs performs better than the overall drug market and
cardiovascular system drugs. The expanding rate of blood lipid-lowering drugs is obviously
higher than that of cardiovascular system drugs and the proportion in the cardiovascular
system drug market is increasing.
Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor, is a
member of the drug class known as statins, used for lowering blood cholesterol. It works
by inhibiting HMG-CoA reductase. In November 2011, Pfizer lost the patent protection in
the USA. In May 2012, Pfizer lost the patent protection in the U.K. either. Liptor is the
most popular drug of Pfizer with the accumulated sales value over USD 100 billion. It is
the first drug with sales value breaking USD 100 billion in the history.
There are many enterprises producing APIs and finished products of atorvastatin. The
market share of finished products is mainly occupied by Pfizer, which is above 80% by
sales value every year. According to CRI's investigation, the CAGR of atorvastatin in
China sample hospital market is above 40% during 2005-2013.
According to clinic research, atorvastatin has certain curative effects on
osteoporosis, Alzheimer's disease, heart disease, organ transplantation, stroke and
Key Topics Covered:
1 Relevant Concepts of Atorvastatin
2 Market Overview of Atorvastatin in China
3 Investigation on Sales Value of Atorvastatin in China, 2009-2013
4 Investigation on Market Share of Major Atorvastatin Manufacturers in China,
5 Investigation on Market Size of Atorvastatin by Dosage Form in China, 2009-2013
6 Reference Price of Atorvastatin in Hospital Market in China, 2013
7 Analysis on Major Atorvastatin Manufacturers in China, 2009-2013
8 Prospect of China Atorvastatin Market, 2014-2018
- Beijing Jialin Pharmaceutical Co., Ltd. - Godecke (GE) - Henan Topfond Pharmaceutical Co., Ltd. - Pfizer
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets